|Bid||3.6000 x 2200|
|Ask||3.8100 x 1800|
|Day's Range||3.6400 - 4.1500|
|52 Week Range||1.4100 - 6.1370|
|Beta (5Y Monthly)||2.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT IND for EPI-7386 Filed On March 31, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced that it submitted an Investigation New Drug (IND) application for EPI-7386, the company’s lead clinical candidate. The company is planning to conduct a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting").
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Additional Preclinical Data Presented on EPI-7386 On February 13, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced additional preclinical data was presented at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (the poster can be found here ) for its lead clinical candidate EPI-7386, which is part
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update ESSA Pharma Inc. (EPIX) is a biopharmaceutical company developing treatments for prostate cancer that is no longer responding to current therapies. The company is developing a series of compounds (‘anitens’) that disrupt the androgen receptor (AR) signaling pathway through a unique mechanism of action that targets
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transducer & Activator of Transcription (STAT) proteins for oncological indications, announced today the appointment of Sanford Zweifach as the Company’s Executive Chairman of the Board of Directors. Mr. Zweifach brings to Janpix almost 30 years of experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Dover, Delaware--(Newsfile Corp. - November 11, 2019) - Encode Ideas, L.P. Initiates Research on ESSA Pharma, Inc. (NASDAQ: EPIX). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on ESSA Pharma, Inc, (NASDAQ: EPIX) as a high conviction investment idea. ESSA is developing a new class of prostate cancer drugs, known as ...
HOUSTON and VANCOUVER , Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.
TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In an oral poster presentation titled, "Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor", further preclinical characterization of EPI-7386 will be presented.
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.